Adcock Ingram Reports Flat Profit Despite Winter Surge
Adcock Ingram reports steady annual profits as winter demand for Panado and Corenza-C drives growth in the second half.
Adcock Ingram to Delist Amidst Corporate Changes
Adcock Ingram is set to delist from the JSE as Natco Pharma partners with Bidvest in a major take-private deal.